SCHEMBL4958290

SCHEMBL4958290

O=C1N=NC(=O)c2c(NF)cccc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.34
MAPT P10636 1/20 0.34
PABPC1 P11940 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAOA P21397 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CASP3 P42574 1/20 0.32
AHR P35869 1/20 0.31
CCNE2 O96020 1/20 0.31
CCNE1 P24864 1/20 0.31
CDK2 P24941 1/20 0.31
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4953834 0.81 EGFR (0.34) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL4956778 0.81 EGFR (0.34) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL4954958 0.81 MAPT (0.34) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL4958351 0.81 MAPT (0.34) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL4958613 0.81 MAPT (0.55) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL4954966 0.81 EGFR (0.34) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL4956575 0.79 MAOA (0.59) RAB9AMAOAKDM4EALDH1A1GAA
SCHEMBL4958638 0.78 PABPC1 (0.41) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL4958192 0.77 DDB1 (0.40) EGFRMAPTPABPC1MAPK1RAB9A
SCHEMBL4953865 0.77 MAPT (0.35) EGFRMAPTPABPC1MAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140030317-A1 MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES Occhiuti & Rohlicek LLP 2014-01-30 US claimed
US-7326690-B2 Modulation of cell fates and activities by phthalazinediones BACH PHARMA, INC. (US) 2008-02-05 US claimed
US-20070142303-A1 Modulation of cell fates and activities by phthalazinediones BACH PHARMA, INC. (US) 2007-06-21 US claimed
US-12246068-B2 Enzymatically activatable peptide-redox modulator conjugates and use thereof BRANDEIS UNIVERSITY (US) 2025-03-11 US disclosed
WO-2018129171-A1 ENZYMATICALLY ACTIVATABLE PEPTIDE-REDOX MODULATOR CONJUGATES AND USE THEREOF BRANDEIS UNIVERSITY (US) 2018-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12246068-B2 Enzymatically activatable peptide-redox modulator conjugates and use thereof GPX1, GPX4, ENPEP EGFR 1247/4885MAPT 4553/4885PABPC1 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.